Conmed vs Haemonetics
Conmed and Haemonetics are similar in size: $1.37bn and $1.33bn of revenue in their latest fiscal years. Conmed grew faster (5.2% against -2.0%). Haemonetics kept more of each dollar of sales as profit: a net margin of 7.3% against 3.4%. Conmed carries less debt relative to equity (80.8% against 155.7%).
| Latest fiscal year | ConmedCNMD, 2025 | HaemoneticsHAE, 2026 |
|---|---|---|
| Revenue | $1.37bn | $1.33bn |
| Revenue growth | 5.2% | -2.0% |
| Net income | $47.1m | $97.3m |
| Operating margin | 7.5% | 11.7% |
| Net margin | 3.4% | 7.3% |
| Return on equity | 4.7% | 12.0% |
| Free cash flow | $151m | $260m |
| Cash | $40.8m | $245m |
| Total debt | $835m | $1.24bn |
| Debt to equity | 80.8% | 155.7% |
| Dividend per share | $0.60 | — |
| Dividend yield | 1.7% | — |
| Share buybacks | — | $175m |
| Employees | 3,900 | — |
| Market value | $1.46bn | $5.49bn |
| Price vs our value range | Below our value range | Above our value range |
| Moat score | 63 (Moderate) | 62 (Moderate) |
| Insider trades, 12 months | 0 buys, 2 sales | 1 buys, 0 sales |